Develops small-molecule drug candidates for psychiatric and neurological disorders and plans to partner with pharmaceutical and biotechnology companies on their development and commercialization.
10-K for FY2025, filed Mar 27, 2026
Works with pharmaceutical and biotechnology companies through licensing and development partnerships: it has licensed drug portfolios to third parties and plans to partner on developing and commercializing psychedelic-inspired medicines.
10-K for FY2025, filed Mar 27, 2026At this stage, we have entered into several non-binding term sheets with strategic partners to out-license certain molecules from the…View ↗
We own rights held by our wholly owned subsidiary Akos Biosciences, Inc. to two active patent families related to cannabinoids. Both patent…View ↗
We intend to focus on the development of novel and viable psychedelic-inspired drug candidates for mental illnesses and unmet medical…View ↗
10-Q for Q3 FY2026, filed Nov 13, 2026
−$2.5MView ↗
Focus on neuropsychiatric drug candidates
The earlier report described developing cancer-related palliative and supportive-care products alongside small-molecule treatments for anxiety, depression and addiction. The latest report centers on non-hallucinogenic neuropsychiatric drug candidates, with its lead candidate as the primary focus.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Mar 27, 2026We are a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression…View ↗
Loading...